Navigation Links
MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Date:8/23/2007

GAITHERSBURG, Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. announced today that it has licensed its proprietary reverse genetics intellectual property to Novartis to support the development and construction of new vaccine strains to produce inactivated human seasonal, pre-pandemic and pandemic influenza vaccines. Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. For prospective pandemic influenza vaccines, reverse genetics can be a useful technology because the process does not require manufacturers to work directly with potentially highly infectious pandemic strains, such as H5N1, rather only segments of the virus's genome.

Most influenza vaccine manufacturing companies and governmental agencies are now using reverse genetics technology in their development of pandemic vaccine candidates because it allows them to avoid working directly with the infectious, circulating pandemic strains. As the owner or exclusive licensee of the key patent estates for use of the reverse genetics technology in human influenza vaccines, MedImmune remains committed to making sure that the technology is accessible to government institutions and industry manufacturers. As such, the company has offered other influenza vaccine manufacturers non-exclusive licenses to this intellectual property estate for use in manufacturing seasonal or pandemic vaccines.

"MedImmune is pleased to have now entered into reverse genetics licensing agreements with three leaders in influenza vaccine development and manufacturing," said Jonathan Klein-Evans, J.D., MedImmune's vice president, intellectual property. "With each new license that expands access to this important technology, the world is advancing its pandemic preparedness as we apply new tools such as reverse genetics to improve and streamline the influenza vaccine development process."

MedImmune will receive an upfront payment and has the potential to receive royalties on ce
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. GenTel licenses next generation cancer research
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. WARF licenses patents for new glaucoma drug treatment
4. PKWARE Licenses Technology to Expand SecureZIP Standard
5. Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility
6. Suggested applications for reverse transcriptases
7. Properties of Reverse Transcriptases
8. Reverse transcriptases suitable for one-step RT-PCRb
9. Reverse transcriptases suitable for two-step RT-PCRd
10. C. therm. Polymerase for Reverse Transcription in Two-Step RT-PCR
11. Choice of reverse transcription primers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... ( www.aapc.com ) announced its 2012 medical coding books ... previous year. Prices have been reduced more than 55 percent over ... reduction was to benefit our more than 100,000 members, non-members of ... Starynskaya, coding books department manager for of AAPC. ...
... (NASDAQ: ITMN ) today announced that it will ... open of the U.S. markets on Thursday, April 28, 2011. ... InterMune at 8:30 a.m. Eastern time that same day. ... 706-643-9223 (international), conference ID# 62213806.  To access the webcast, please ...
... Eigen is the proud recipient of two grant awards ... U.S. Department of Health & Human Services. QTDP tax credits ... (IRC), enacted as part of the Patient Protection and Affordable ... $244,000 award for each grant awarded in October, 2010, and ...
Cached Biology Technology:AAPC Lowers Prices on Medical Coding Books, Again 2Eigen Receives Two Grant Awards from U.S. Department of Health & Human Services 2
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... select partners? Darwin,s initial idea that the fittest males ... likely to secure partners has represented a cornerstone of evolutionary ... 1871. Darwin proposed that secondary sexual characteristics enabled females ... best for every female. This male would be the ...
... three percent (n=181) of patients in the study cohort ... their arthritis developed a first cancer within nine years ... of arthritis. The nine year follow-up study conducted ... ((RR)=1.03 (95%confidence interval 0.82-1.30)) was not increased in patients ...
... Scientists from the University of Warwick have discovered ... be ,ultra-bad, leading to increased risk of heart disease. ... heart disease particularly in people with type 2 diabetes ... British Heart Foundation (BHF), found that ,ultrabad, cholesterol, called ...
Cached Biology News:The importance of 'inner values' -- female sparrows test the genetic make-up of their mates 2Arthritis patients taking newer treatments do not have an overall increased cancer risk 2Super-sticky 'ultra-bad' cholesterol revealed in people at high risk of heart disease 2
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
... Ambions MAXIscript In Vitro Transcription Kits synthesize ... x 10 9 cpm/g. High specific ... ribonuclease protection assays, in situ hybridization, and ... used for the synthesis of modest amounts ...
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
Request Info...
Biology Products: